Biological Therapy in IBD
- 1 July 2003
- journal article
- review article
- Published by S. Karger AG in Digestive Diseases
- Vol. 21 (2) , 180-191
- https://doi.org/10.1159/000073249
Abstract
Currently used standard treatment in IBD is effective and sufficient for the majority of patients. Published numbers regarding therapy refractoriness are probably related to referral centers and not representative. Pharmacological optimization of available drugs improves the standard situation further. Biological therapies in a larger meaning are studied intensively, but obviously hopes are to some extent not real. Biological and for some principles clinical effects (i.e. TNF antibodies, CD4 antibodies) are proven, the effects are, however, limited and long-term risks and results are not clarified. Numerous approaches are not clinically relevantly effective which is, in particular, true for those inhibiting single mediators. A number of alternative concepts such as hormones and growth factors could be effective and will be studied further. In particular probiotics may be a development of the future and they belong to the ‘biologic treatments’ in the true sense.Keywords
This publication has 33 references indexed in Scilit:
- Treatment of active Crohn's disease with onercept (recombinant human soluble p55 tumour necrosis factor receptor): results of a randomized, open‐label, pilot studyAlimentary Pharmacology & Therapeutics, 2003
- Anti–tumor necrosis factor therapy and Listeria monocytogenes infection: Report of two casesArthritis & Rheumatism, 2002
- Maintenance infliximab for Crohn's disease: the ACCENT I randomised trialPublished by Elsevier ,2002
- Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin‐1 receptor antagonist, in combination with methotrexate: Results of a twenty‐four–week, multicenter, randomized, double‐blind, placebo‐controlled trialArthritis & Rheumatism, 2002
- Randomized, controlled trial of recombinant human interleukin‐11 in patients with active Crohn's diseaseAlimentary Pharmacology & Therapeutics, 2002
- Endosonographic Evidence of Persistence of Crohn's Disease-Associated Fistulas After Infliximab Treatment, Irrespective of Clinical ResponseDiseases of the Colon & Rectum, 2002
- Tuberculosis Associated with Infliximab, a Tumor Necrosis Factor α–Neutralizing AgentNew England Journal of Medicine, 2001
- Interleukin 10 (Tenovil) in the prevention of postoperative recurrence of Crohn's diseaseGut, 2001
- Infliximab for the Treatment of Fistulas in Patients with Crohn's DiseaseNew England Journal of Medicine, 1999
- Antibodies to interleukin 12 abrogate established experimental colitis in mice.The Journal of Experimental Medicine, 1995